- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01144988
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma (AVIRMA01-09)
An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas
Malignant glioma are the most common and aggressive primary brain tumors in adults. Despite advances in multimodal treatment including surgery, radiation and chemotherapy, most patients have a dismal prognosis of 9-15 months (Stupp et al., NEJM 2005).
A major reason for the aggressiveness of malignant glioma is a pronounced tumor neovascularization, mainly driven by the vascular endothelial growth factor (VEGF) and its receptors. The therapeutic monoclonal antibody Bevacizumab (Avastin®) inhibits the VEGF pathway by binding the VEGF ligand. In Magnetic Resonance Imaging (MRI) this treatment reduces contrast enhancement by restoring both, the blood-brain-barrier and the destabilized vessel integrity. Furthermore, it raises the sensitivity of co-administered chemotherapeutics such as Irinotecan. In conclusion, anti-angiogenic therapy leads to the problem that the routinely used MRI techniques cannot distinguish anti-vascular effects from true anti-tumor effects.
The study hypothesis of the clinical trial part is that in 35% of malignant glioma patients Avastin / Irinotecan chemotherapy results in objective tumor responses assessed by standard / functional MRI and FET- /FLT-PET neuroimaging. The study hypothesis for the translational study part is that the expression of the molecular targets of Avastin and Irinotecan in malignant glioma tissue ( = tumor and vascular cells) are predictive for Avastin / Irinotecan therapy induced treatment response measured by functional MRI and FET- / FLT-PET imaging.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Guenther Stockhammer, MD, Prof.
- E-post: guenther.stockhammer@i-med.ac.at
Studer Kontakt Backup
- Navn: Markus Hutterer, MD
- E-post: m.hutterer@salk.at
Studiesteder
-
-
-
Innsbruck, Østerrike, A-6020
- Rekruttering
- Medical University Innsbruck, Department for Neurology
-
Ta kontakt med:
- Guenther Stockhammer, MD, Prof.
- E-post: guenther.stockhammer@i-med.ac.at
-
Ta kontakt med:
- Martha Nowosielski, MD
- E-post: Martha.Nowosielski@i-med.ac.at
-
Hovedetterforsker:
- Guenther Stockhammer, MD, Prof.
-
Underetterforsker:
- Martha Nowosielski, MD
-
Underetterforsker:
- Markus Glatzer, MD
-
Salzburg, Østerrike, 5020
- Rekruttering
- Paracelsus Medical University, Christian Doppler Klinik
-
Ta kontakt med:
- Markus Hutterer, MD
- E-post: m.hutterer@salk.at
-
Hovedetterforsker:
- Stefan Golaszewski, MD
-
Underetterforsker:
- Markus Hutterer, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients present with a first or second tumor recurrence / progression of a histological confirmed supratentorial malignant glioma WHO Grade III-IV (Classification following WHO criteria).
Patients with surgical resection of tumor recurrence / progression: Following standard therapy(first recurrence) or standard therapy / second line chemotherapy (second recurrence, excepting antiangiogenic approaches) patients must have evidence of further tumor progression measured by standard MRI sequences (MacDonald criteria). If possible, patients may have prior surgical resection of the tumor progression and will be eligible if the following conditions apply:
- Patients must have recovered from the effects of surgery
- To adequately asses the malignant glioma before surgery and the extent of residual disease postoperatively, two MRIs scans have to be performed:
- A first standard MRI scan has to be done within 1 week before surgery to document a progressed or recurrent malignant glioma.
- A second standard / functional MRI scan has to be done between 24 and 48 hours after surgery to document the postoperative malignant glioma (Baseline MRI scan).
- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document the postoperative malignant glioma (Baseline PET scans).
Patients without surgical resection of the tumor recurrence / progression: Patients must have evidence of tumor progression measured by standard MRI sequences (MacDonald criteria).
- Additional functional MRI sequences have to be done within 1 week prior to study enrollment.
- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document the postoperative malignant glioma (Baseline PET scans).
- Resolution of all acute toxic effects of prior therapy to grade ≤ 1 (except alopecia)
- Patients must have an ECOG performance status of 0-2
- Patients must be ≥ 18 years and ≤ 80 years of age, with a life expectancy of greater than 8 weeks
Patients must have adequate organ function as defined by the following criteria:
Bone Marrow Reserve
- Platelets ≥ 75.000/μL
- Absolute Neutrophil Count ≥ 1500/μL
- Hemoglobin ≥ 10.0 g/dL Blood Coagulation
- aPTT ≤ 1.5 times upper limit of normal (ULN) Hepatic Function
- ASAT and ALAT ≤ 2.5 times ULN
- ALP ≤ 2.5 times ULN
- Total SERUM Bilirubin < 1.5 times ULN Renal Function
- SERUM Creatinine ≤ 1.5 times ULN Metabolism
- SERUM Albumin ≥ 3.0 g/dL All tests must be performed ≤ 3 days prior to study enrollment. Eligibility for hemoglobin count may be reached by transfusion.
- Signed and dated informed consent document by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrollment.
Willingness and ability of the patient to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
- The patient is active participant in another clinical trial, which investigates substances with antiangiogenic effectiveness
Exclusion of patients in the event of
- surgery of a recurrent / progressed malignant glioma within 2 weeks prior to study enrollment
- chemotherapy (Standard therapy o Second Line Chemotherapy) within 2 weeks prior to study enrollment
- radiation therapy (Standard therapy) within4 weeks to study enrollment
- evidence in baseline MRI of intratumoral or peritumoral hemorrhage deemed clinically significant by the treating physician (area of hemorrhage > 25% of tumor area)
Significant Co-Morbidities within 12 months prior to study enrollment
- myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure
- cerebrovascular accident including transient ischemic attack
Significant Co-Morbidities at Baseline Evaluation
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
- Pulmonary embolism within 4 weeks before study enrollment
- A known HIV (human immunodeficiency virus) or Hepatitis B/C infection or severe acute infection
- Anticoagulation: Current treatment with therapeutic doses of Marcoumar / Sintrom excluding thrombosis prophylaxis with low dose Heparin
Pregnancy, Breastfeeding and Non-Contraception
- Female patients who are pregnant or nursing
- Patients who are sexually active and unwilling or unable to use a medically acceptable method of contraception during the trial
Evidence of increased intracranial pressure
- midline shift > 5 mm
- headache, distinct nausea and vomiting
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart excess risk associated with study participation or study drug administration, or which would make the patient inappropriate for entry into this study. The decision to enroll the patient in this study is in the judgment of the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To determine the objective tumor response criteria (RR, ORR, ORD) assessed by Standard MRI and FET-/FLT-PET during Avastin / Irinotecan chemotherapy.
Tidsramme: three years
|
three years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Evaluation of the predictive / prognostic value of the VEGF pathway and tumor cell proliferation rate in tumor and vascular cells of malignant gliomas treated with Avastin / Irinotecan Chemotherapy
Tidsramme: three years
|
three years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Guenther Stockhammer, MD, Prof., Department for Neurology, Medical University Innsbruck
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer, kjertel og epitel
- Sykdomsattributter
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Tilbakefall
- Glioma
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Topoisomerasehemmere
- Antineoplastiske midler, immunologiske
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Topoisomerase I-hemmere
- Bevacizumab
- Irinotekan
Andre studie-ID-numre
- EUDRACT-Nr: 2009-015036-15
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tilbakevendende ondartet gliom
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Aktiv, ikke rekrutterendeGenmodifiserte T-celler i behandling av pasienter med tilbakevendende eller refraktært malignt gliomTilbakevendende glioblastom | Tilbakevendende ondartet gliom | Ildfast malignt gliom | Tilbakevendende WHO Grad III Gliom | Tilbakevendende WHO grad II Gliom | Ildfast glioblastom | Ildfast WHO Grade II Gliom | Ildfast WHO Grade III GliomForente stater
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRekrutteringGlioblastom | Ondartet gliom | Tilbakevendende glioblastom | Tilbakevendende WHO Grad III Gliom | WHO Grad III Gliom | IDH2-genmutasjon | IDH1 genmutasjon | Gliom av lav grad | Tilbakevendende WHO grad II Gliom | WHO Grad II GliomForente stater
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRekrutteringGlioma | Gliom av høy grad | Gliom, ondartet | Diffus gliom | Gliom intrakranieltForente stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeGlioblastom | Ondartet gliom | WHO Grad III Gliom | Tilbakevendende gliom | Ildfast gliomForente stater
-
Hospital del Río HortegaFullførtGlioma | Glioblastom | Gliom av lav kvalitet | Gliom, ondartet | Gliom av høy kvalitetSpania
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRekrutteringGlioblastom | Ondartet gliom | Tilbakevendende glioblastom | Tilbakevendende ondartet gliom | Tilbakevendende grad III Gliom | Grad III GliomForente stater, Australia, Israel, Sveits
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationHar ikke rekruttert ennåGlioma | Gliom av lav kvalitet | Gliom, ondartet | Lavgradig hjernegliom | Gliom intrakranieltForente stater
-
National Cancer Institute (NCI)RekrutteringGlioma | Gliom av høy grad | Ondartet gliom | Gliomer | Gliom av lav gradForente stater
-
Susan ChangGE Healthcare; Sigma-Aldrich; Phillips-MedisizeRekrutteringTilbakevendende WHO Grad III Gliom | WHO Grad III Gliom | WHO Grad II Gliom | Tilbakevendende gliom av grad II fra Verdens helseorganisasjon (WHO).Forente stater
-
Beijing Tiantan HospitalDuke UniversityUkjentGlioblastom | Gliom av høy grad | Gliom, ondartet | Gliom av hjernestammeKina
Kliniske studier på Bevacizumab / Irinotecan
-
Cancer Institute and Hospital, Chinese Academy...RekrutteringMetastatisk tykktarmskreftKina
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsFullførtTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Platina-resistent egglederkarsinom | Platina-resistent primært peritonealt karsinom | Platina-resistent ovariekarsinom | Ildfast ovariekarsinom | Ildfast egglederkarsinom | Refraktært primært...Forente stater
-
Taiho Pharmaceutical Co., Ltd.Fullført
-
National Cancer Institute (NCI)FullførtPineoblastom | Tilbakevendende medulloblastom | Ildfast medulloblastom | Refraktær perifer primitiv nevroektodermal svulst | Neoplasma i sentralnervesystemet | Tilbakevendende primitiv nevroektodermal svulstForente stater, Canada, Puerto Rico, Australia, New Zealand
-
Cancer Institute and Hospital, Chinese Academy...UkjentTykktarmskreft | Metastatisk kreft | Kolorektalt adenokarsinomKina
-
CytoVac A/SAvsluttetGlioblastoma MultiformeDanmark
-
PfizerFullførtKolorektale neoplasmerAustralia, Canada, Forente stater, New Zealand
-
Shanghai Zhangjiang Biotechnology Limited CompanyShanghai Biomabs Pharmaceutical Co., Ltd.FullførtMetastatisk tykktarmskreft
-
Ottawa Hospital Research InstituteSanofi; Pfizer; Hoffmann-La Roche; Ottawa Regional Cancer FoundationAvsluttetMetastatisk tykktarmskreftCanada
-
Centre Oscar LambretSFCEFullført